| Field | Row 1 |
|---|---|
| adsh | 0001437749-25-015966 |
| cik | 1053691 |
| name | CERVOMED INC. |
| sic | 2834 |
| countryba | US |
| stprba | MA |
| cityba | BOSTON |
| zipba | 02116 |
| bas1 | 20 PARK PLAZA |
| bas2 | SUITE 424 |
| baph | (617) 744-4400 |
| countryma | US |
| stprma | MA |
| cityma | BOSTON |
| zipma | 02116 |
| mas1 | 20 PARK PLAZA |
| mas2 | SUITE 424 |
| countryinc | US |
| stprinc | DE |
| ein | 300645032 |
| former | DIFFUSION PHARMACEUTICALS INC. |
| changed | 20160115 |
| afs | 4-NON |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250512 |
| accepted | 2025-05-12 09:07:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | crvo20250331_10q_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001437749-25-015966 | 20241231 | Accounts Payable Current | 1511440.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | General And Administrative Expense | 2127930.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Increase Decrease In Accounts Payable | -230403.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Increase Decrease In Accounts Receivable | -915404.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Increase Decrease In Accrued Liabilities | -285439.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20241231 | Liabilities | 3879282.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Liabilities And Stockholders Equity | 38577488.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Other Accrued Liabilities Current | 2082403.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | -34974.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20241231 | Preferred Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2025 | Class Of Stock= Series A Preferred Stock; | ||
| 0001437749-25-015966 | 20241231 | Prepaid Expenses Deposits And Other Assets | 1905360.0000 | USD | 0 | 0001437749-25-015966 | |||
| 0001437749-25-015966 | 20241231 | Retained Earnings Accumulated Deficit | -70731484.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Share Based Compensation | 218215.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Stockholders Equity | 6170.0000 | USD | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20250331 | Stockholders Equity | 21223.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001437749-25-015966 | 20240229 | Stock Issued During Period Shares Exercise Of Warrants | 495959.0000 | shares | 0 | 0001437749-25-015966 | Class Of Warrant Or Right= Prefunded Warrant; | ||
| 0001437749-25-015966 | 20240331 | Stock Issued During Period Value Exercise Of Warrants | -496.0000 | USD | 1 | 0001437749-25-015966 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-015966 | 20250331 | Accounts Payable Current | 1860598.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 218215.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20241231 | Cash And Cash Equivalents At Carrying Value | 8999496.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Common Stock Value | 8702.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Comprehensive Income Net Of Tax | -2514335.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Comprehensive Income Net Of Tax | -4929008.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Grants Receivable Current | 1629227.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Increase Decrease In Accrued Liabilities | -268696.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Increase Decrease In Deferred Revenue | 572475.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Increase Decrease In Deferred Revenue | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 116334.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Liabilities | 3943001.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20241231 | Liabilities And Stockholders Equity | 43081610.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Net Cash Provided By Used In Investing Activities | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20241231 | Other Accrued Liabilities Current | 2367842.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20241231 | Preferred Stock Shares Authorized | 30000000.0000 | shares | 0 | us-gaap/2025 | Class Of Stock= Series A Preferred Stock; | ||
| 0001437749-25-015966 | 20241231 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2025 | Class Of Stock= Series A Preferred Stock; | ||
| 0001437749-25-015966 | 20241231 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2025 | Class Of Stock= Series A Preferred Stock; | ||
| 0001437749-25-015966 | 20240331 | Revenues | 2347250.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Revenues | 1917491.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Shares Outstanding | 6170479.0000 | shares | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20241231 | Shares Outstanding | 8702719.0000 | shares | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20231231 | Stockholders Equity | 7376774.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20241231 | Stockholders Equity | 39202328.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20241231 | Stockholders Equity | 56197.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001437749-25-015966 | 20241231 | Stockholders Equity | 8702.0000 | USD | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-015966 | 20250331 | Common Stock Shares Outstanding | 8702719.0000 | shares | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Investment Income Interest | 408985.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Net Cash Provided By Used In Operating Activities | -3894359.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Net Income Loss | -2514335.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Net Income Loss | -4894034.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Operating Expenses | 4942188.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Other Nonoperating Income Expense | -30.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20241231 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2025 | Class Of Stock= Series A Preferred Stock; | ||
| 0001437749-25-015966 | 20250331 | Research And Development Expense | 4837798.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Revenues | 2300000.0000 | USD | 1 | us-gaap/2025 | Type Of Arrangement= National Institute Of Aging Grant; | ||
| 0001437749-25-015966 | 20241130 | Stock Issued During Period Shares Exercise Of Warrants | 448978.0000 | shares | 0 | 0001437749-25-015966 | Class Of Warrant Or Right= Prefunded Warrant; | ||
| 0001437749-25-015966 | 20240331 | Stock Issued During Period Value Exercise Of Warrants | 496.0000 | USD | 1 | 0001437749-25-015966 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20240331 | Stock Issued During Period Value Exercise Of Warrants | 0.0000 | USD | 1 | 0001437749-25-015966 | Equity Components= Retained Earnings; | ||
| 0001437749-25-015966 | 20240331 | Stock Issued During Period Value Issued For Services | 255724.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-015966 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 361167.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001437749-25-015966 | 20241231 | Assets | 43081610.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 1502218.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20241231 | Common Stock Shares Authorized | 1000000000.0000 | shares | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Common Stock Shares Issued | 8702719.0000 | shares | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Earnings Per Share Basic | -0.4100 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20241231 | Grants Receivable Current | 2254231.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Marketable Securities Unrealized Gain Loss | -34974.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Net Income Loss | -2514335.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-015966 | 20250331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001437749-25-015966 | 20250331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20250331 | Operating Income Loss | -5302884.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2025 | Class Of Stock= Series A Preferred Stock; | ||
| 0001437749-25-015966 | 20240331 | Proceeds From Sale And Maturity Of Marketable Securities | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20140831 | Research And Development Expense | 100000.0000 | USD | 0 | us-gaap/2025 | Type Of Arrangement= Vertex Option And License Agreement; | ||
| 0001437749-25-015966 | 20240331 | Research And Development Expense | 2814258.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Stockholders Equity | -75625518.0000 | USD | 0 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-015966 | 20240331 | Stock Issued During Period Shares Exercise Of Warrants | 495959.0000 | shares | 1 | 0001437749-25-015966 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20240331 | Stock Issued During Period Shares Issued For Services | 0.0000 | shares | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20240331 | Stock Issued During Period Value Issued For Services | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-015966 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 6170501.0000 | shares | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20241231 | Additional Paid In Capital | 109868913.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Additional Paid In Capital | 110230080.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20241231 | Common Stock Shares Issued | 8702719.0000 | shares | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Earnings Per Share Basic | -0.5600 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Accretion Expense Net | -251828.0000 | USD | 1 | 0001437749-25-015966 | |||
| 0001437749-25-015966 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-015966 | 20250331 | Assets Current | 38577488.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 10501714.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2025 | ||||
| 0001437749-25-015966 | 20250331 | Common Stock Shares Authorized | 1000000000.0000 | shares | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Investment Income Interest | 80633.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20241231 | Marketable Securities Current | 29922523.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Net Income Loss | -4894034.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-015966 | 20250331 | Operating Expenses | 7220375.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | -34974.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001437749-25-015966 | 20250331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-015966 | 20250331 | Proceeds From Sale And Maturity Of Marketable Securities | 12500000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20231231 | Shares Outstanding | 5674520.0000 | shares | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20240331 | Stockholders Equity | 5336378.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Stockholders Equity | 34634487.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Stock Issued During Period Value Issued For Services | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 8702719.0000 | shares | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Accretion Expense Net | 0.0000 | USD | 1 | 0001437749-25-015966 | |||
| 0001437749-25-015966 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 7792846.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -1423674.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20241231 | Common Stock Shares Outstanding | 8702719.0000 | shares | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Debt Offering Costs Incurred During Noncash Or Partial Noncash Transaction | 0.0000 | USD | 1 | 0001437749-25-015966 | |||
| 0001437749-25-015966 | 20250331 | General And Administrative Expense | 2382577.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Increase Decrease In Accounts Receivable | -625004.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Net Cash Provided By Used In Investing Activities | 5396577.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20240331 | Operating Income Loss | -2594938.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Preferred Stock Shares Authorized | 30000000.0000 | shares | 0 | us-gaap/2025 | Class Of Stock= Series A Preferred Stock; | ||
| 0001437749-25-015966 | 20250331 | Prepaid Expenses Deposits And Other Assets | 1703747.0000 | USD | 0 | 0001437749-25-015966 | |||
| 0001437749-25-015966 | 20250331 | Revenues | 1900000.0000 | USD | 1 | us-gaap/2025 | Type Of Arrangement= National Institute Of Aging Grant; | ||
| 0001437749-25-015966 | 20231231 | Stockholders Equity | 61811889.0000 | USD | 0 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-015966 | 20240331 | Stock Issued1 | 255724.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20241231 | Assets Current | 43081610.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 6369172.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Debt Offering Costs Incurred During Noncash Or Partial Noncash Transaction | 247671.0000 | USD | 1 | 0001437749-25-015966 | |||
| 0001437749-25-015966 | 20250331 | Increase Decrease In Accounts Payable | 349158.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -201613.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Marketable Securities Current | 24742800.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Nonoperating Income Expense | 408850.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20250331 | Other Nonoperating Income Expense | -135.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2025 | Class Of Stock= Series A Preferred Stock; | ||
| 0001437749-25-015966 | 20250331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2025 | Class Of Stock= Series A Preferred Stock; | ||
| 0001437749-25-015966 | 20250331 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2025 | Class Of Stock= Series A Preferred Stock; | ||
| 0001437749-25-015966 | 20250331 | Retained Earnings Accumulated Deficit | -75625518.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Shares Outstanding | 8702719.0000 | shares | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20231231 | Stockholders Equity | 5674.0000 | USD | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20231231 | Stockholders Equity | -54440789.0000 | USD | 0 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-015966 | 20241231 | Stockholders Equity | 109868913.0000 | USD | 0 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-015966 | 20250331 | Stockholders Equity | 8702.0000 | USD | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-015966 | 20240331 | Stock Issued During Period Value Exercise Of Warrants | 0.0000 | USD | 1 | 0001437749-25-015966 | |||
| 0001437749-25-015966 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | 56197.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | 21223.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Assets | 38577488.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Cash And Cash Equivalents At Carrying Value | 10501714.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 8999496.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Cashless Exercise Of Warrants | 496.0000 | USD | 1 | 0001437749-25-015966 | |||
| 0001437749-25-015966 | 20250331 | Cashless Exercise Of Warrants | 0.0000 | USD | 1 | 0001437749-25-015966 | |||
| 0001437749-25-015966 | 20241231 | Common Stock Value | 8702.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Marketable Securities Unrealized Gain Loss | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Net Cash Provided By Used In Operating Activities | -1423674.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Nonoperating Income Expense | 80603.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Payments To Acquire Marketable Securities | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Payments To Acquire Marketable Securities | 7103423.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20250331 | Share Based Compensation | 361167.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Stockholders Equity | 62285332.0000 | USD | 0 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-015966 | 20240331 | Stockholders Equity | -56955124.0000 | USD | 0 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-015966 | 20241231 | Stockholders Equity | -70731484.0000 | USD | 0 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-015966 | 20250331 | Stockholders Equity | 110230080.0000 | USD | 0 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-015966 | 20250331 | Stock Issued1 | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-015966 | 20240331 | Stock Issued During Period Value Issued For Services | 255724.0000 | USD | 1 | us-gaap/2025 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Investing Activities | us-gaap/2025 | 0 | 0 | monetary | D | D | Cash Provided by (Used in) Investing Activity, Including Discontinued Operation | Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets. |
| Stock Issued1 | us-gaap/2025 | 0 | 0 | monetary | D | C | Stock Issued | The fair value of stock issued in noncash financing activities. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2025 | 0 | 0 | monetary | I | D | Cash and Cash Equivalent | Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. |
| Common Stock Shares Authorized | us-gaap/2025 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2025 | 0 | 0 | monetary | D | D | Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation | Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. |
| Grants Receivable Current | us-gaap/2025 | 0 | 0 | monetary | I | D | Grants Receivable, Current | Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. |
| General And Administrative Expense | us-gaap/2025 | 0 | 0 | monetary | D | D | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. |
| Commitments And Contingencies | us-gaap/2025 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Investment Income Interest | us-gaap/2025 | 0 | 0 | monetary | D | C | Investment Income, Interest | Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. |
| Other Accrued Liabilities Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Other Accrued Liabilities, Current | Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. |
| Additional Paid In Capital | us-gaap/2025 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Common Stock Shares Issued | us-gaap/2025 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Increase Decrease In Accounts Payable | us-gaap/2025 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Operating Income Loss | us-gaap/2025 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Accretion Expense Net | 0001437749-25-015966 | 1 | 0 | monetary | D | D | Accretion of discount on marketable securities, net | Amount of accretion of discount on marketable securities, net |
| Comprehensive Income Net Of Tax | us-gaap/2025 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2025 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Operating Expenses | us-gaap/2025 | 0 | 0 | monetary | D | D | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | us-gaap/2025 | 0 | 0 | monetary | D | C | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax | Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. |
| Payments To Acquire Marketable Securities | us-gaap/2025 | 0 | 0 | monetary | D | C | Payments to Acquire Marketable Securities | Amount of cash outflow for purchase of marketable security. |
| Research And Development Expense | us-gaap/2025 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Stock Issued During Period Value Issued For Services | us-gaap/2025 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Issued for Services | Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2025 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. | |
| Earnings Per Share Basic | us-gaap/2025 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2025 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Shares Outstanding | us-gaap/2025 | 0 | 0 | shares | I | Shares, Outstanding | Number of shares issued which are neither cancelled nor held in the treasury. | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2025 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Preferred Stock Shares Issued | us-gaap/2025 | 0 | 0 | shares | I | Preferred Stock, Shares Issued | Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. | |
| Prepaid Expenses Deposits And Other Assets | 0001437749-25-015966 | 1 | 0 | monetary | I | D | Prepaid expenses and other current assets | Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Stock Issued During Period Shares Exercise Of Warrants | 0001437749-25-015966 | 1 | 0 | shares | D | Cashless exercise of pre-funded warrants (in shares) | Number of shares issued during period for exercise of warrants. | |
| Common Stock Shares Outstanding | us-gaap/2025 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Marketable Securities Current | us-gaap/2025 | 0 | 0 | monetary | I | D | Marketable Securities, Current | Amount of investment in marketable security, classified as current. |
| Nonoperating Income Expense | us-gaap/2025 | 0 | 0 | monetary | D | C | Nonoperating Income (Expense) | The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). |
| Proceeds From Sale And Maturity Of Marketable Securities | us-gaap/2025 | 0 | 0 | monetary | D | D | Proceeds from Sale and Maturity of Marketable Securities | The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. |
| Stock Issued During Period Shares Issued For Services | us-gaap/2025 | 0 | 0 | shares | D | Stock Issued During Period, Shares, Issued for Services | Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. | |
| Assets | us-gaap/2025 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Increase Decrease In Accounts Receivable | us-gaap/2025 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Liabilities And Stockholders Equity | us-gaap/2025 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Net Income Loss | us-gaap/2025 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Other Nonoperating Income Expense | us-gaap/2025 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Stockholders Equity | us-gaap/2025 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2025 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2025 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Cashless Exercise Of Warrants | 0001437749-25-015966 | 1 | 0 | monetary | D | C | crvo_CashlessExerciseOfWarrants | Amount of cashless exercise of warrants in noncash investing and financing transaction. |
| Stock Issued During Period Value Exercise Of Warrants | 0001437749-25-015966 | 1 | 0 | monetary | D | C | Cashless exercise of pre-funded warrants | Value of stock issued during period for exercise of warrants. |
| Assets Current | us-gaap/2025 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Revenues | us-gaap/2025 | 0 | 0 | monetary | D | C | Revenues | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). |
| Liabilities | us-gaap/2025 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Increase Decrease In Accrued Liabilities | us-gaap/2025 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accrued Liabilities | The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. |
| Preferred Stock Shares Authorized | us-gaap/2025 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Preferred Stock Shares Outstanding | us-gaap/2025 | 0 | 0 | shares | I | Preferred Stock, Shares Outstanding | Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. | |
| Share Based Compensation | us-gaap/2025 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Accounts Payable Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2025 | 0 | 0 | monetary | I | D | Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation | Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. |
| Increase Decrease In Deferred Revenue | us-gaap/2025 | 0 | 0 | monetary | D | D | Increase (Decrease) in Deferred Revenue | Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. |
| Marketable Securities Unrealized Gain Loss | us-gaap/2025 | 0 | 0 | monetary | D | C | Marketable Security, Unrealized Gain (Loss) | Amount of unrealized gain (loss) on investment in marketable security. |
| Preferred Stock Value | us-gaap/2025 | 0 | 0 | monetary | I | C | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Debt Offering Costs Incurred During Noncash Or Partial Noncash Transaction | 0001437749-25-015966 | 1 | 0 | monetary | D | C | Deferred offering costs in accounts payable and accrued expenses | The amount of debt offering costs that were incurred during a noncash or partial noncash transaction. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2025 | 0 | 0 | monetary | D | Cash Provided by (Used in) Operating Activity, Including Discontinued Operation | Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity. | |
| Retained Earnings Accumulated Deficit | us-gaap/2025 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Common Stock Value | us-gaap/2025 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001437749-25-015966 | 2 | 7 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2025 | Cash and cash equivalents | 0 |
| 0001437749-25-015966 | 2 | 8 | BS | 0 | H | Marketable Securities Current | us-gaap/2025 | Marketable securities | 0 |
| 0001437749-25-015966 | 2 | 9 | BS | 0 | H | Prepaid Expenses Deposits And Other Assets | 0001437749-25-015966 | Prepaid expenses and other current assets | 0 |
| 0001437749-25-015966 | 2 | 10 | BS | 0 | H | Grants Receivable Current | us-gaap/2025 | Grant receivable | 0 |
| 0001437749-25-015966 | 2 | 11 | BS | 0 | H | Assets Current | us-gaap/2025 | Total current assets | 0 |
| 0001437749-25-015966 | 2 | 12 | BS | 0 | H | Assets | us-gaap/2025 | Total assets | 0 |
| 0001437749-25-015966 | 2 | 14 | BS | 0 | H | Accounts Payable Current | us-gaap/2025 | Accounts payable | 0 |
| 0001437749-25-015966 | 2 | 15 | BS | 0 | H | Other Accrued Liabilities Current | us-gaap/2025 | Accrued expenses and other current liabilities | 0 |
| 0001437749-25-015966 | 2 | 16 | BS | 0 | H | Liabilities | us-gaap/2025 | Total liabilities | 0 |
| 0001437749-25-015966 | 2 | 17 | BS | 0 | H | Commitments And Contingencies | us-gaap/2025 | Commitments and Contingencies | 0 |
| 0001437749-25-015966 | 2 | 19 | BS | 0 | H | Preferred Stock Value | us-gaap/2025 | Series A preferred stock $0.001 par value; 30,000,000 authorized at March 31, 2025 and December 31, 2024, 0 shares issued and outstanding at March 31, 2025 and December 31, 2024 | 0 |
| 0001437749-25-015966 | 2 | 20 | BS | 0 | H | Common Stock Value | us-gaap/2025 | Common stock, $0.001 par value: 1,000,000,000 shares authorized: 8,702,719 shares issued and outstanding at March 31, 2025 and December 31, 2024 | 0 |
| 0001437749-25-015966 | 2 | 21 | BS | 0 | H | Additional Paid In Capital | us-gaap/2025 | Additional paid-in capital | 0 |
| 0001437749-25-015966 | 2 | 22 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2025 | Accumulated other comprehensive income | 0 |
| 0001437749-25-015966 | 2 | 23 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2025 | Accumulated deficit | 0 |
| 0001437749-25-015966 | 2 | 24 | BS | 0 | H | Stockholders Equity | us-gaap/2025 | Total stockholders' equity | 0 |
| 0001437749-25-015966 | 2 | 25 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2025 | Total liabilities and stockholders' equity | 0 |
| 0001437749-25-015966 | 3 | 6 | BS | 1 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2025 | Preferred Stock, Par or Stated Value Per Share (in dollars per share) | 0 |
| 0001437749-25-015966 | 3 | 7 | BS | 1 | H | Preferred Stock Shares Authorized | us-gaap/2025 | Preferred Stock, Shares Authorized (in shares) | 0 |
| 0001437749-25-015966 | 3 | 8 | BS | 1 | H | Preferred Stock Shares Outstanding | us-gaap/2025 | Preferred Stock, Shares Outstanding (in shares) | 0 |
| 0001437749-25-015966 | 3 | 9 | BS | 1 | H | Preferred Stock Shares Issued | us-gaap/2025 | Preferred Stock, Shares Issued (in shares) | 0 |
| 0001437749-25-015966 | 3 | 10 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2025 | Common Stock, Par or Stated Value Per Share (in dollars per share) | 0 |
| 0001437749-25-015966 | 3 | 11 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2025 | Common Stock, Shares Authorized (in shares) | 0 |
| 0001437749-25-015966 | 3 | 12 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2025 | Common Stock, Shares, Issued (in shares) | 0 |
| 0001437749-25-015966 | 3 | 13 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2025 | Common Stock, Shares, Outstanding (in shares) | 0 |
| 0001437749-25-015966 | 4 | 3 | IS | 0 | H | Revenues | us-gaap/2025 | Grant revenue | 0 |
| 0001437749-25-015966 | 4 | 5 | IS | 0 | H | Research And Development Expense | us-gaap/2025 | Research and development | 0 |
| 0001437749-25-015966 | 4 | 6 | IS | 0 | H | General And Administrative Expense | us-gaap/2025 | General and administrative | 0 |
| 0001437749-25-015966 | 4 | 7 | IS | 0 | H | Operating Expenses | us-gaap/2025 | Total operating expenses | 0 |
| 0001437749-25-015966 | 4 | 8 | IS | 0 | H | Operating Income Loss | us-gaap/2025 | Loss from operations | 0 |
| 0001437749-25-015966 | 4 | 10 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2025 | Other expense | 0 |
| 0001437749-25-015966 | 4 | 11 | IS | 0 | H | Investment Income Interest | us-gaap/2025 | Interest income | 0 |
| 0001437749-25-015966 | 4 | 12 | IS | 0 | H | Nonoperating Income Expense | us-gaap/2025 | Total other income, net | 0 |
| 0001437749-25-015966 | 4 | 13 | IS | 0 | H | Net Income Loss | us-gaap/2025 | Net loss | 0 |
| 0001437749-25-015966 | 4 | 15 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2025 | Net loss per share of common stock, basic and diluted (in dollars per share) | 0 |
| 0001437749-25-015966 | 4 | 16 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2025 | Weighted average shares outstanding, basic and diluted (in shares) | 0 |
| 0001437749-25-015966 | 4 | 17 | IS | 0 | H | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | us-gaap/2025 | Net unrealized loss on marketable securities | 0 |
| 0001437749-25-015966 | 4 | 18 | IS | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2025 | Total comprehensive loss | 0 |
| 0001437749-25-015966 | 5 | 9 | EQ | 0 | H | Shares Outstanding | us-gaap/2025 | Balance (in shares) | 0 |
| 0001437749-25-015966 | 5 | 10 | EQ | 0 | H | Stockholders Equity | us-gaap/2025 | Balance | 0 |
| 0001437749-25-015966 | 5 | 11 | EQ | 0 | H | Stock Issued During Period Shares Issued For Services | us-gaap/2025 | Stock options granted in lieu of bonus compensation (in shares) | 0 |
| 0001437749-25-015966 | 5 | 12 | EQ | 0 | H | Stock Issued During Period Value Issued For Services | us-gaap/2025 | Stock options granted in lieu of bonus compensation | 0 |
| 0001437749-25-015966 | 5 | 13 | EQ | 0 | H | Stock Issued During Period Shares Exercise Of Warrants | 0001437749-25-015966 | Cashless exercise of pre-funded warrants (in shares) | 0 |
| 0001437749-25-015966 | 5 | 14 | EQ | 0 | H | Stock Issued During Period Value Exercise Of Warrants | 0001437749-25-015966 | Cashless exercise of pre-funded warrants | 0 |
| 0001437749-25-015966 | 5 | 15 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2025 | Stock-based compensation expense | 0 |
| 0001437749-25-015966 | 5 | 16 | EQ | 0 | H | Net Income Loss | us-gaap/2025 | Net loss | 0 |
| 0001437749-25-015966 | 5 | 17 | EQ | 0 | H | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | us-gaap/2025 | Net unrealized loss on marketable securities | 0 |
| 0001437749-25-015966 | 5 | 18 | EQ | 0 | H | Shares Outstanding | us-gaap/2025 | Balance (in shares) | 0 |
| 0001437749-25-015966 | 5 | 19 | EQ | 0 | H | Stockholders Equity | us-gaap/2025 | Balance | 0 |
| 0001437749-25-015966 | 6 | 4 | CF | 0 | H | Net Income Loss | us-gaap/2025 | Net loss | 0 |
| 0001437749-25-015966 | 6 | 6 | CF | 0 | H | Accretion Expense Net | 0001437749-25-015966 | Accretion of discount on marketable securities, net | 0 |
| 0001437749-25-015966 | 6 | 7 | CF | 0 | H | Share Based Compensation | us-gaap/2025 | Stock-based compensation expense | 0 |
| 0001437749-25-015966 | 6 | 9 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2025 | Prepaid expenses, deposits and other assets | 1 |
| 0001437749-25-015966 | 6 | 10 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2025 | Grant receivable | 1 |
| 0001437749-25-015966 | 6 | 11 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2025 | Accounts payable | 0 |
| 0001437749-25-015966 | 6 | 12 | CF | 0 | H | Increase Decrease In Accrued Liabilities | us-gaap/2025 | Accrued expenses and other liabilities | 0 |
| 0001437749-25-015966 | 6 | 13 | CF | 0 | H | Increase Decrease In Deferred Revenue | us-gaap/2025 | Deferred grant revenue | 0 |
| 0001437749-25-015966 | 6 | 14 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2025 | Net cash used in operating activities | 0 |
| 0001437749-25-015966 | 6 | 16 | CF | 0 | H | Payments To Acquire Marketable Securities | us-gaap/2025 | Purchase of marketable securities | 1 |
| 0001437749-25-015966 | 6 | 17 | CF | 0 | H | Proceeds From Sale And Maturity Of Marketable Securities | us-gaap/2025 | Maturities of marketable securities | 0 |
| 0001437749-25-015966 | 6 | 18 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2025 | Net cash provided by investing activities | 0 |
| 0001437749-25-015966 | 6 | 19 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2025 | Net increase (decrease) in cash and cash equivalents | 0 |
| 0001437749-25-015966 | 6 | 20 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2025 | Cash and cash equivalents at beginning of period | 0 |
| 0001437749-25-015966 | 6 | 21 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2025 | Cash and cash equivalents at end of period | 0 |
| 0001437749-25-015966 | 6 | 23 | CF | 0 | H | Debt Offering Costs Incurred During Noncash Or Partial Noncash Transaction | 0001437749-25-015966 | Deferred offering costs in accounts payable and accrued expenses | 0 |
| 0001437749-25-015966 | 6 | 24 | CF | 0 | H | Marketable Securities Unrealized Gain Loss | us-gaap/2025 | Unrealized loss on marketable securities | 0 |
| 0001437749-25-015966 | 6 | 25 | CF | 0 | H | Stock Issued1 | us-gaap/2025 | Stock options granted in lieu of cash bonus | 0 |
| 0001437749-25-015966 | 6 | 26 | CF | 0 | H | Cashless Exercise Of Warrants | 0001437749-25-015966 | Cashless exercise of prefunded warrants | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |